Monday, 24 June 2024

World’s first and only oral cholera vaccine in LDPE unidose pack launches in India

12 May 2023 | News

TechInvention recently received approval by the CDSCO for the launch of Euvichol-Plus following the completion of a phase III clinical study

TechInvention Lifecare in India, has partnered with Eubiologics Co. in  South Korea,  to  launch Euvichol-Plus,  the  world’s  first  and  only  oral  cholera vaccine (OCV), in a low-density polyethylene (LDPE) unidose pack in India.

The LDPE unidose pack of Euvichol-Plus is not only easy and safe to use, but it also reduces the issues pertaining  to  conventional  glass  vials  in  terms  of  breakage,  storage,  transportation,  distribution,  waste management, and facilitates delivery in emergency situations and humanitarian crises in campaign mode.

TechInvention recently received approval by the regulatory body Central Drugs Standard Control Organisation (CDSCO) for the launch of Euvichol-Plus following the completion of a phase III clinical study.

While cholera remains a major global public health threat, there has been an alarming resurgence of cases in susceptible countries globally amidst the stoppage in production of one of the only two cholera vaccines.

India features at the top of the list of cholera- endemic countries, with an estimated incidence rate of 1.64 per 1,000 people. In India, estimates show that 400 million people are at risk of cholera, with an estimated 6,751,888 cases and 20,256 (3%) deaths annually. 

TechInvention's Founder and CEO, Syed Ahmed said, "We wish to contribute to the national initiatives along the lines of WHO's ‘Ending Cholera: A Global Roadmap by  2030’.  TechInvention has  2 more  vaccines in late-stage clinical development and regulatory approval in India, while there are more on the anvil."

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account